Full text is available at the source.
Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases
Bone-driven production of a cell receptor helps target nanotherapy to breast cancer spread
AI simplified
Abstract
Integrin β3 was significantly elevated on bone metastases in 42 breast cancer patients compared to primary tumors.
- Bone metastases occur in approximately 70% of metastatic breast cancer patients, often leading to skeletal injuries.
- In a preclinical model, integrin β3 was strongly expressed on bone metastatic cancer cells but not on primary mammary tumors or visceral metastases.
- Mechanistic investigations indicated that TGFβ signaling through SMAD2/SMAD3 is necessary for the induction of β3 in breast cancer within the bone.
- A micelle-based nanoparticle therapy targeting integrin αvβ3 demonstrated specific localization to breast cancer bone metastases in mice.
- Using this targeted delivery system for docetaxel, bone tumor burden was significantly reduced with less bone destruction and reduced hepatotoxicity compared to free docetaxel.
- Mice treated with the nanoparticle-encapsulated docetaxel showed a significant decrease in tumor cell proliferation within the bone compared to those treated with free docetaxel.
AI simplified